Polymer- and Lipid-Based Systems for Parenteral Drug Delivery

Chapter
Part of the AAPS Advances in the Pharmaceutical Sciences Series book series (AAPS, volume 6)

Abstract

The field of drug delivery technology research has continued to grow in recent decades, expanding from technologies traditionally focused on controlled release to now include nanotechnologies and functionalized molecular architectures for target-specific delivery. While these emerging novel technologies are beginning to mature, many of the clinical applications of controlled-release drug delivery technologies continue to focus on well-characterized biodegradable polymer particles, in situ forming gel depots, and lipid-based particulate formulations. This review principally focuses on the physicochemical and functional characteristics of in situ forming semisolid depot formulations and lipid-based drug delivery technologies and also discusses the broader considerations in bringing drug delivery-enabled products to market.

Keywords

Cholesterol Surfactant Glycol Syringe Sarcoma 

References

  1. Aggarwal S (2011) What’s fueling the biotech engine—2010 to 2011. Nat Biotechnol 29(12):1083–1089PubMedCrossRefGoogle Scholar
  2. Barenholz Y (2012) Doxil—the first FDA-approved nano-drug : lessons learned. J Control Release 160(2):117–134PubMedCrossRefGoogle Scholar
  3. Benesch M, Urban C (2008) Liposomal cytarabine for leukemic and lymphomatous meningitis: recent developments. Expert Opin Pharmacother 9(2):301–309PubMedCrossRefGoogle Scholar
  4. Brodbeck KJ, DesNoyer JR, McHugh AJ (1999) Phase inversion dynamics of PLGA solutions related to drug delivery. Part II. The role of solution thermodynamics and bath-side mass transfer. J Control Release 62(3):333–344PubMedCrossRefGoogle Scholar
  5. Chen S, Pieper R, Webster DC, Singh J (2005) Triblock copolymers: synthesis, characterization, and delivery of a model protein. Int J Pharm 288(2):207–218PubMedCrossRefGoogle Scholar
  6. Davis FF (2002) The origin of pegnology. Adv Drug Deliv Rev 54(4):457–458PubMedCrossRefGoogle Scholar
  7. Davis SS (2004) Coming of age of lipid-based drug delivery systems. Adv Drug Deliv Rev 56(9):1241–1242PubMedCrossRefGoogle Scholar
  8. Davis ME, Chen ZG, Shin DM (2008) Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 7(9):771–782PubMedCrossRefGoogle Scholar
  9. Deamer D, Bangham AD (1976) Large volume liposomes by an ether vaporization method. Biochim Biophys Acta 443(3):629–634PubMedCrossRefGoogle Scholar
  10. Dunn RL (2002) The atrigel drug delivery system. In: Rathbone MJ, Hadgraft J, Roberts MS (eds) Modified Release Drug Delivery Technology. Marcel Dekker, New York, pp 647–656Google Scholar
  11. Dunn DL, English JP, Cowsar DR, Vanderbelt DP (1990) Biodegradable in situ forming implants and methods of producing the same. US Patent 4,938,763Google Scholar
  12. ElBayoumi TA, Torchilin VP (2009) Current trends in liposome research. In: Weissig V (ed) Liposomes, methods and protocols. Springer, New York, pp 1–27Google Scholar
  13. Elstad NL, Fowers KD (2009) OncoGel (ReGel/paclitaxel)—clinical applications for a novel paclitaxel delivery system. Adv Drug Deliv Rev 61(10):785–794PubMedCrossRefGoogle Scholar
  14. Fahy E, Subramaniam S, Brown HA, Glass CK, Merrill AH Jr, Murphy RC, Raetz CR, Russell DW, Seyama Y, Shaw W, Shimizu T, Spener F, van Meer G, VanNieuwenhze MS, White SH, Witztum JL, Dennis EA (2005) A comprehensive classification system for lipids. J Lipid Res 46(5):839–861PubMedCrossRefGoogle Scholar
  15. Fahy E, Sud M, Cotter D, Subramaniam S (2007) LIPID MAPS online tools for lipid research. Nucleic Acids Res 35(Web Server issue):W606–W612PubMedCrossRefGoogle Scholar
  16. Forssen EA (1997) The design and development of DaunoXome® for solid tumor targeting in vivo. Adv Drug Deliv Rev 24:133–150CrossRefGoogle Scholar
  17. Gabizon A, Shmeeda H, Barenholz Y (2003) Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet 42(5):419–436PubMedCrossRefGoogle Scholar
  18. Gershkovich P, Wasan KM, Barta CA (2008) A review of the application of lipid-based systems in systemic, dermal/transdermal, and ocular drug delivery. Crit Rev Ther Drug Carrier Syst 25(6):545–584PubMedCrossRefGoogle Scholar
  19. Graham PD, Brodbeck KJ, McHugh AJ (1999) Phase inversion dynamics of PLGA solutions related to drug delivery. J Control Release 58(2):233–245PubMedCrossRefGoogle Scholar
  20. Harris JM, Chess RB (2003) Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2(3):214–221PubMedCrossRefGoogle Scholar
  21. He C, Kim SW, Lee DS (2008) In situ gelling stimuli-sensitive block copolymer hydrogels for drug delivery. J Control Release 127(3):189–207PubMedCrossRefGoogle Scholar
  22. Janoff AS (1999) Liposomes as pharmaceuticals. In: Jannoff AS (ed) Liposomes: rational design. Marcel Dekker, New York, pp xix–xxxiGoogle Scholar
  23. Jaspart S, Bertholet P, Piel G, Dogne JM, Delattre L, Evrard B (2007) Solid lipid microparticles as a sustained release system for pulmonary drug delivery. Eur J Pharm Biopharm 65(1):47–56PubMedCrossRefGoogle Scholar
  24. Jeong B, Kim SW, Bae YH (2002) Thermosensitive sol–gel reversible hydrogels. Adv Drug Deliv Rev 54(1):37–51PubMedCrossRefGoogle Scholar
  25. Kabanov AV, Batrakova EV, Alakhov VY (2002) Pluronic block copolymers for overcoming drug resistance in cancer. Adv Drug Deliv Rev 54(5):759–779PubMedCrossRefGoogle Scholar
  26. Kohane DS (2007) Microparticles and nanoparticles for drug delivery. Biotechnol Bioeng 96(2):203–209PubMedCrossRefGoogle Scholar
  27. Kozlowski A, Charles SA, Harris JM (2001) Development of pegylated interferons for the treatment of chronic hepatitis C. BioDrugs 15(7):419–429PubMedCrossRefGoogle Scholar
  28. Langer R (1990) New methods of drug delivery. Science 249(4976):1527–1533PubMedCrossRefGoogle Scholar
  29. Lasic DD (1998) Novel applications of liposomes. Trends Biotechnol 16(7):307–321PubMedCrossRefGoogle Scholar
  30. Lian T, Ho RJ (2001) Trends and developments in liposome drug delivery systems. J Pharm Sci 90(6):667–680PubMedCrossRefGoogle Scholar
  31. Mehnert W, Mader K (2001) Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 47(2–3):165–196PubMedCrossRefGoogle Scholar
  32. Muller RH, Radtke M, Wissing SA (2002) Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 54(Suppl 1):S131–S155PubMedCrossRefGoogle Scholar
  33. Muller RH, Petersen RD, Hommoss A, Pardeike J (2007) Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Rev 59(6):522–530PubMedCrossRefGoogle Scholar
  34. Okada H, Toguchi H (1995) Biodegradable microspheres in drug delivery. Crit Rev Ther Drug Carrier Syst 12(1):1–99PubMedCrossRefGoogle Scholar
  35. Okumu FW, Dao le N, Fielder PJ, Dybdal N, Brooks D, Sane S, Cleland JL (2002) Sustained delivery of human growth hormone from a novel gel system: SABER. Biomaterials 23(22):4353–4358PubMedCrossRefGoogle Scholar
  36. Packhaeuser CB, Schnieders J, Oster CG, Kissel T (2004) In situ forming parenteral drug delivery systems: an overview. Eur J Pharm Biopharm 58(2):445–455PubMedCrossRefGoogle Scholar
  37. Puri A, Loomis K, Smith B, Lee J, Yavlovich A, Heldman E, Blumental R (2009) Lipid-based nanoparticles as pharmaceutical drug carriers: from concept to clinic. Crit Rev Ther Drug Carrier Syst 26(6):523–580PubMedCrossRefGoogle Scholar
  38. Reithmeier H, Herrmann J, Gopferich A (2001) Lipid microparticles as a parenteral controlled release device for peptides. J Control Release 73(2–3):339–350PubMedCrossRefGoogle Scholar
  39. Reynolds RC (1998) Metabolism and pharmacokinetics of sucrose acetate isobutyrate (SAIB) and sucrose octaisobutyrate (SOIB) in rats, dogs, monkeys or humans: a review. Food Chem Toxicol 36(2):95–99PubMedCrossRefGoogle Scholar
  40. Reynolds RC, Chappel CI (1998) Sucrose acetate isobutyrate (SAIB): historical aspects of its use in beverages and a review of toxicity studies prior to 1988. Food Chem Toxicol 36(2):81–93PubMedCrossRefGoogle Scholar
  41. Saraf S, Mishra D, Asthana A, Jain R, Singh S, Jain NK (2006) Lipid microparticles for mucosal immunization against hepatitis B. Vaccine 24(1):45–56PubMedCrossRefGoogle Scholar
  42. Sartor O (2003) Eligard: leuprolide acetate in a novel sustained-release delivery system. Urology 61(2 Suppl 1):25–31PubMedCrossRefGoogle Scholar
  43. Skubitz KM, Haddad PA (2005) Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer 104(2):361–366PubMedCrossRefGoogle Scholar
  44. Spira J, Plyushch OP, Andreeva TA, Khametova RN (2008) Evaluation of liposomal dose in recombinant factor VIII reconstituted with pegylated liposomes for the treatment of patients with severe haemophilia A. Thromb Haemost 100(3):429–434PubMedGoogle Scholar
  45. Sriadibhatla S, Yang Z, Gebhart C, Alakhov VY, Kabanov A (2006) Transcriptional activation of gene expression by pluronic block copolymers in stably and transiently transfected cells. Mol Ther 13(4):804–813PubMedCrossRefGoogle Scholar
  46. Van Tomme SR, Storm G, Hennink WE (2008) In situ gelling hydrogels for pharmaceutical and biomedical applications. Int J Pharm 355(1–2):1–18PubMedCrossRefGoogle Scholar
  47. Wissing SA, Muller RH (2002) Solid lipid nanoparticles as carrier for sunscreens: in vitro release and in vivo skin penetration. J Control Release 81(3):225–233PubMedCrossRefGoogle Scholar
  48. Wissing SA, Kayser O, Muller RH (2004a) Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 56(9):1257–1272PubMedCrossRefGoogle Scholar
  49. Wissing SA, Muller RH, Manthei L, Mayer C (2004b) Structural characterization of Q10-loaded solid lipid nanoparticles by NMR spectroscopy. Pharm Res 21(3):400–405PubMedCrossRefGoogle Scholar
  50. Yu L, Chang GT, Zhang H, Ding JD (2008) Injectable block copolymer hydrogels for sustained release of a PEGylated drug. Int J Pharm 348(1–2):95–106PubMedCrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2013

Authors and Affiliations

  1. 1.Biotherapeutics Pharmaceutical SciencesPfizer, Inc.AndoverUSA
  2. 2.Parenteral Formulation SciencesMillennium: The Takeda Oncology CompanyCambridgeUSA

Personalised recommendations